- Previous Rank28
- Revenue 3 Yr Annual Growth Rate25%
- Revenue 3 Yr Growth Rank61
- EPS 3 Yr Annual Growth Rate65%
- EPS 3 Yr Growth Rank25
- Total Return 3 Yr Annual Rate23%
- Total Return 3 Yr Rank54
Growth in its DNA: The world’s largest genetic sequencing company is launching a startup, Grail, to develop blood-based screenings for early cancer detection.
Looking for leads, investment insights, or competitive intelligence?Buy Now
Company Information
| Location | San Diego, Calif. |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Current Streak | 2 |
| Years on List | 4 |
| CEO | Francis deSouza |
| Website | http://www.illumina.com |
Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.
Revenue, Net Income
| Revenue Past Four Quarters ($M) | $2,253 |
| Net Income Past Four Quarters ($M) | $414 |
Growth Rates and Ranks
| Revenue 3 Yr Growth Rank | 61 |
| EPS 3 Yr Annual Growth Rate | 65% |
| EPS 3 Yr Growth Rank | 25 |
| Total Return 3 Yr Annual Rate | 23% |
| Total Return 3 Yr Rank | 54 |
